Entacom Plus 50 Tablet is a combination pharmaceutical formulation containing Levodopa (50mg), Carbidopa (12.5mg), and Entacapone (200mg), primarily indicated for the management of Parkinson’s disease. Levodopa serves as a precursor to dopamine, effectively replenishing diminished dopamine levels in the brain, thereby alleviating motor symptoms such as bradykinesia, rigidity, and tremors. Carbidopa is a peripheral dopa-decarboxylase inhibitor that prevents the peripheral conversion of Levodopa to dopamine, enhancing central nervous system availability and reducing peripheral side effects like nausea and cardiovascular disturbances. Entacapone, a selective and reversible catechol-O-methyltransferase (COMT) inhibitor, extends the half-life of Levodopa by inhibiting its peripheral metabolism, thus improving symptomatic control and reducing “wearing-off” phenomena associated with Levodopa monotherapy. The combined action of these agents offers improved motor symptom management and a more stable dopaminergic effect. Entacom Plus 50 is typically administered orally, with dosing individualized based on clinical response and tolerability. Patients should be monitored for potential adverse effects including dyskinesia, orthostatic hypotension, hallucinations, and gastrointestinal disturbances. Caution is advised in patients with cardiovascular disorders, hepatic impairment, or a history of neuroleptic malignant syndrome. This combination therapy represents an advanced approach in optimizing Parkinson’s disease treatment outcomes.